Global Health Ltd
Global Health Limited operates a network of multi-specialty tertiary and quaternary care hospitals under the Medanta brand, primarily across North and East India. The company specialises in cardiac sciences, oncology, neurosciences, digestive and hepatobiliary sciences, orthopaedics, organ transplantation, kidney and urology, and other complex medical procedures. As of June 2026, Medanta operated six hospitals across Gurugram, Lucknow, Patna, Ranchi, Indore and Noida, supported by an expanding diagnostics, pharmacy and outpatient network. [1]
- Market Cap ₹ 37,381 Cr.
- Current Price ₹ 1,390
- High / Low ₹ 1,544 / 955
- Stock P/E 68.0
- Book Value ₹ 160
- Dividend Yield 0.04 %
- ROCE 16.4 %
- ROE 13.2 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 54.3% CAGR over last 5 years
Cons
- Stock is trading at 8.66 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Hospital
Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap Select Index BSE 150 MidCap Index
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1,277 | 1,343 | 1,441 | 1,472 | 1,227 | 1,765 | 1,974 | 2,975 | 3,204 | 3,709 | 4,188 | |
| Sales growth | +5% | +7% | +2% | -17% | +44% | +12% | +51% | +8% | +16% | +22% | |
| 1,158 | 1,218 | 1,297 | 1,253 | 1,054 | 1,384 | 1,551 | 2,222 | 2,432 | 2,946 | 3,300 | |
| Operating Profit | 119 | 125 | 144 | 219 | 173 | 381 | 423 | 753 | 772 | 764 | 888 |
| OPM % | 9% | 9% | 10% | 15% | 14% | 22% | 21% | 25% | 24% | 21% | 21% |
| 67 | 49 | 64 | 43 | 28 | 35 | 47 | 91 | 41 | 107 | 75 | |
| Interest | 19 | 24 | 21 | 33 | 29 | 33 | 32 | 51 | 41 | 50 | 60 |
| Depreciation | 77 | 86 | 91 | 99 | 88 | 87 | 86 | 134 | 150 | 171 | 211 |
| Profit before tax | 89 | 64 | 97 | 131 | 84 | 296 | 352 | 659 | 623 | 650 | 693 |
| Tax % | 39% | 42% | 35% | 22% | 32% | 26% | 25% | 26% | 26% | 24% | |
| 54 | 37 | 63 | 103 | 57 | 219 | 263 | 486 | 462 | 496 | 523 | |
| EPS in Rs | 2.24 | 1.54 | 2.56 | 4.17 | 2.31 | 8.64 | 9.82 | 18.11 | 17.18 | 18.46 | 19.44 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 3% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 25% |
| 3 Years: | 23% |
| TTM: | 22% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 54% |
| 3 Years: | 23% |
| TTM: | 5% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 18% |
| 1 Year: | 11% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 15% |
| 3 Years: | 15% |
| Last Year: | 13% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 48 | 48 | 49 | 49 | 50 | 51 | 54 | 54 | 54 | 54 | 54 |
| Reserves | 1,070 | 1,141 | 1,230 | 1,341 | 1,434 | 1,689 | 2,435 | 2,983 | 3,444 | 3,959 | 4,260 |
| 215 | 201 | 168 | 51 | 228 | 308 | 288 | 424 | 337 | 683 | 343 | |
| 303 | 318 | 310 | 517 | 291 | 314 | 402 | 523 | 606 | 656 | 1,330 | |
| Total Liabilities | 1,637 | 1,709 | 1,758 | 1,958 | 2,002 | 2,361 | 3,179 | 3,984 | 4,441 | 5,351 | 5,986 |
| 966 | 1,162 | 869 | 929 | 851 | 827 | 810 | 1,645 | 1,861 | 2,903 | 3,061 | |
| CWIP | 8 | 7 | 5 | 3 | 4 | 6 | 75 | 280 | 458 | 120 | 199 |
| Investments | 21 | 0 | 356 | 500 | 626 | 734 | 765 | 362 | 366 | 389 | 389 |
| 642 | 540 | 528 | 525 | 521 | 794 | 1,529 | 1,698 | 1,757 | 1,939 | 2,337 | |
| Total Assets | 1,637 | 1,709 | 1,758 | 1,958 | 2,002 | 2,361 | 3,179 | 3,984 | 4,441 | 5,351 | 5,986 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 124 | 152 | 193 | 201 | 235 | 431 | 559 | 528 | 573 | ||
| -112 | -104 | -45 | -250 | -313 | -257 | -519 | -638 | -931 | ||
| -6 | -49 | -56 | -37 | 98 | 404 | -379 | -94 | 264 | ||
| Net Cash Flow | 6 | -1 | 92 | -86 | 20 | 577 | -339 | -205 | -94 | |
| Free Cash Flow | 34 | 123 | 176 | 178 | 171 | 315 | 335 | 102 | -102 | |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 153% | 153% | 114% | 125% | 86% | 126% | 97% | 89% | 89% |
Ratios
Standalone / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 31 | 41 | 42 | 37 | 39 | 36 | 32 | 26 | 33 | 38 |
| Inventory Days | 36 | 26 | 26 | 37 | 39 | 33 | 34 | 29 | 24 | 23 |
| Days Payable | 132 | 124 | 142 | 135 | 134 | 84 | 113 | 84 | 81 | 93 |
| Cash Conversion Cycle | -66 | -56 | -74 | -61 | -56 | -16 | -48 | -29 | -24 | -32 |
| Working Capital Days | -31 | -16 | -7 | -11 | -20 | -6 | -27 | -24 | -14 | -4 |
| ROCE % | 6% | 8% | 11% | 7% | 17% | 16% | 23% | 20% | 16% |
Insights
In beta| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| ALOS (Average Length of Stay) days |
|
|||||||
| ARPOB (Average Revenue Per Occupied Bed) INR |
||||||||
| Bed Occupancy Rate % |
||||||||
| Census Beds (Operational Capacity) count |
||||||||
| In-Patient Volume (IPD) count |
||||||||
| Out-Patient Volume (OPD) count |
||||||||
| Total Beds (Installed Capacity) count |
||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- Audio recording of Q2 and H1 FY2026 earnings conference call released.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper publication under Regulation 30 and 47 of SEBI Listing Regulations.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
- Investor Presentation for the Second Quarter and Half Year ended September 30, 2026, Results.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
- Q2FY27 results strong; board approved 500-bed Ghaziabad hospital with ~INR 9,970 million capex.
-
Announcement Under Regulation 30 Of Listing Regulations.
- Board approved Q2 FY27 results and Rs 997 crore 500-bed Ghaziabad hospital project.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
Concalls
-
Nov 2026PPT REC
-
Aug 2026Transcript PPT REC
-
May 2026Transcript PPT REC
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT
-
May 2025PPT
-
Feb 2025Transcript PPT REC
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
Aug 2023PPT
-
Jun 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Dec 2022PPT
Hospital Count
Global Health operates 6 hospitals across Gurugram, Indore, Ranchi, Lucknow, Patna and Noida, with 3,737 installed beds as of June 2026 across 5.6 million sq. ft. The network has 950+ ICU beds and offers services across 30+ medical specialties. Gurugram is the flagship hospital, while Lucknow, Patna and Noida form the newer hospital portfolio where capacity and clinical services are being scaled.[1]